Stock INO INOVIO PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Inovio Pharmaceuticals, Inc.

Equities

INO

US45773H4092

Real-time Estimate Cboe BZX
Other stock markets
 09:35:23 2024-04-16 am EDT 		5-day change 1st Jan Change
8.865 USD -19.34% Intraday chart for Inovio Pharmaceuticals, Inc. -3.09% +79.58%
Mar. 06 Transcript : Inovio Pharmaceuticals, Inc., Q4 2023 Earnings Call, Mar 06, 2024
Mar. 06 Inovio Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
INOVIO to Participate in The Citizens JMP Novel Therapeutics Forum at Penn Medicine
PR
INOVIO Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
AQ
Transcript : Inovio Pharmaceuticals, Inc., Q4 2023 Earnings Call, Mar 06, 2024
Inovio Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
INOVIO to Report Fourth Quarter and Year-End 2023 Financial Results on March 6, 2024
PR
INOVIO to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
PR
INOVIO Reports Inducement Grant Under Inducement Plan
PR
Oppenheimer Upgrades Inovio Pharmaceuticals to Outperform From Perform, $4 Price Target
MT
Reverse Split: 1 of 12
FA
Transcript : Inovio Pharmaceuticals, Inc. - Special Call
INOVIO Announces Effective Date of 1-for-12 Reverse Stock Split
PR
INOVIO to Participate in Virtual Fireside Chat on the Potential Treatment of Recurrent Respiratory Papillomatosis with Key Opinion Leader
PR
Inovio Pharmaceuticals, Coherus BioSciences to Collaborate on Potential Throat Cancer Treatment
MT
INOVIO and Coherus Announces Clinical Collaboration to Advance Development of INO-3112 in Combination with LOQTORZI?? (toripalimab-Ttzi)
CI
Inovio Pharmaceuticals Plans BLA Submission for INO-3107 for Recurrent Respiratory Papillomatosis Treatment
MT
INOVIO Plans to Submit a BLA for INO-3107 as a Potential Treatment for RRP in Second Half of 2024 Under Accelerated Approval Program
CI
INOVIO Plans to Submit a BLA for INO-3107 as a Potential Treatment for RRP in Second Half of 2024 Under Accelerated Approval Program
PR
Inovio Pharmaceuticals, Inc.(NasdaqCM:INO) dropped from NASDAQ Biotechnology Index
CI
Inovio: Q3 Earnings Snapshot
AQ
Transcript : Inovio Pharmaceuticals, Inc., Q3 2023 Earnings Call, Nov 09, 2023
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. INO Stock
  4. News Inovio Pharmaceuticals, Inc.